| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Shoulder Joint | 185 | 2023 | 656 | 26.950 |
Why?
|
| Arthroplasty, Replacement, Shoulder | 59 | 2023 | 212 | 14.320 |
Why?
|
| Baseball | 38 | 2022 | 103 | 13.330 |
Why?
|
| Rotator Cuff Injuries | 73 | 2023 | 316 | 10.860 |
Why?
|
| Tenodesis | 40 | 2023 | 174 | 10.700 |
Why?
|
| Arthroscopy | 126 | 2023 | 1105 | 10.550 |
Why?
|
| Joint Instability | 61 | 2021 | 395 | 9.070 |
Why?
|
| Rotator Cuff | 65 | 2023 | 308 | 8.740 |
Why?
|
| Shoulder Injuries | 43 | 2023 | 144 | 8.320 |
Why?
|
| Tendon Injuries | 36 | 2023 | 205 | 7.130 |
Why?
|
| Elbow Joint | 30 | 2022 | 126 | 6.810 |
Why?
|
| Range of Motion, Articular | 97 | 2021 | 719 | 6.090 |
Why?
|
| Humans | 384 | 2023 | 25900 | 6.030 |
Why?
|
| Tendons | 34 | 2023 | 221 | 5.860 |
Why?
|
| Return to Sport | 24 | 2021 | 158 | 5.850 |
Why?
|
| Collateral Ligament, Ulnar | 12 | 2022 | 26 | 5.680 |
Why?
|
| Shoulder Dislocation | 24 | 2021 | 111 | 5.550 |
Why?
|
| Athletic Injuries | 30 | 2020 | 172 | 5.540 |
Why?
|
| Shoulder | 35 | 2021 | 187 | 5.390 |
Why?
|
| Osteoarthritis | 24 | 2023 | 333 | 4.760 |
Why?
|
| Orthopedic Procedures | 28 | 2020 | 314 | 4.660 |
Why?
|
| Ulnar Collateral Ligament Reconstruction | 9 | 2022 | 17 | 4.630 |
Why?
|
| Postoperative Complications | 42 | 2023 | 893 | 4.560 |
Why?
|
| Muscle, Skeletal | 31 | 2023 | 378 | 4.550 |
Why?
|
| Scapula | 28 | 2022 | 90 | 4.460 |
Why?
|
| Humerus | 32 | 2022 | 107 | 4.450 |
Why?
|
| Male | 195 | 2022 | 14176 | 4.210 |
Why?
|
| Treatment Outcome | 114 | 2023 | 3339 | 4.080 |
Why?
|
| Arthroplasty, Replacement | 24 | 2020 | 150 | 4.060 |
Why?
|
| Adult | 144 | 2022 | 7517 | 4.050 |
Why?
|
| Middle Aged | 150 | 2022 | 8556 | 3.840 |
Why?
|
| Glenoid Cavity | 12 | 2022 | 38 | 3.840 |
Why?
|
| Reoperation | 44 | 2020 | 912 | 3.630 |
Why?
|
| Hemiarthroplasty | 10 | 2019 | 37 | 3.610 |
Why?
|
| Collateral Ligaments | 7 | 2022 | 26 | 3.490 |
Why?
|
| Retrospective Studies | 90 | 2023 | 3342 | 3.470 |
Why?
|
| Biomechanical Phenomena | 54 | 2022 | 639 | 3.380 |
Why?
|
| Female | 173 | 2022 | 14543 | 3.360 |
Why?
|
| Shoulder Pain | 20 | 2020 | 58 | 3.270 |
Why?
|
| Young Adult | 60 | 2022 | 1929 | 3.070 |
Why?
|
| Arthroplasty | 19 | 2022 | 159 | 3.050 |
Why?
|
| Shoulder Prosthesis | 13 | 2022 | 23 | 2.850 |
Why?
|
| Tendinopathy | 11 | 2020 | 54 | 2.700 |
Why?
|
| Aged | 105 | 2022 | 8658 | 2.460 |
Why?
|
| Adolescent | 53 | 2021 | 2070 | 2.410 |
Why?
|
| Ligaments, Articular | 9 | 2019 | 109 | 2.310 |
Why?
|
| Follow-Up Studies | 43 | 2021 | 1708 | 2.260 |
Why?
|
| Bone Screws | 17 | 2020 | 142 | 2.250 |
Why?
|
| Suture Techniques | 31 | 2020 | 158 | 2.220 |
Why?
|
| Tenotomy | 6 | 2021 | 20 | 2.200 |
Why?
|
| Pectoralis Muscles | 7 | 2016 | 18 | 2.150 |
Why?
|
| Shoulder Fractures | 7 | 2020 | 33 | 2.080 |
Why?
|
| Athletic Performance | 5 | 2020 | 20 | 1.970 |
Why?
|
| Osteotomy | 11 | 2022 | 172 | 1.960 |
Why?
|
| Tibia | 8 | 2018 | 246 | 1.860 |
Why?
|
| Recovery of Function | 24 | 2019 | 296 | 1.810 |
Why?
|
| Hamstring Muscles | 3 | 2019 | 19 | 1.760 |
Why?
|
| Patient Readmission | 5 | 2019 | 128 | 1.750 |
Why?
|
| Tomography, X-Ray Computed | 18 | 2020 | 631 | 1.680 |
Why?
|
| Suture Anchors | 14 | 2020 | 101 | 1.670 |
Why?
|
| Postoperative Period | 19 | 2021 | 331 | 1.640 |
Why?
|
| Patient Satisfaction | 12 | 2021 | 314 | 1.630 |
Why?
|
| Fracture Fixation, Internal | 3 | 2019 | 58 | 1.610 |
Why?
|
| Cadaver | 36 | 2020 | 375 | 1.580 |
Why?
|
| Acromioclavicular Joint | 8 | 2019 | 16 | 1.520 |
Why?
|
| Joint Prosthesis | 6 | 2015 | 89 | 1.460 |
Why?
|
| Acromion | 7 | 2021 | 28 | 1.420 |
Why?
|
| Radiography | 25 | 2020 | 611 | 1.400 |
Why?
|
| Bone Transplantation | 11 | 2019 | 203 | 1.400 |
Why?
|
| Orthopedics | 5 | 2020 | 113 | 1.370 |
Why?
|
| Aged, 80 and over | 44 | 2021 | 4633 | 1.360 |
Why?
|
| Upper Extremity | 7 | 2019 | 62 | 1.360 |
Why?
|
| Superficial Back Muscles | 3 | 2021 | 4 | 1.360 |
Why?
|
| Databases, Factual | 14 | 2020 | 328 | 1.350 |
Why?
|
| Decompression, Surgical | 8 | 2019 | 124 | 1.340 |
Why?
|
| Rotator Cuff Tear Arthropathy | 5 | 2021 | 14 | 1.320 |
Why?
|
| Rotation | 19 | 2021 | 138 | 1.290 |
Why?
|
| United States | 23 | 2023 | 1935 | 1.260 |
Why?
|
| Athletes | 8 | 2022 | 87 | 1.240 |
Why?
|
| Time Factors | 22 | 2020 | 1376 | 1.240 |
Why?
|
| Pain Measurement | 20 | 2020 | 477 | 1.230 |
Why?
|
| Bankart Lesions | 2 | 2020 | 14 | 1.230 |
Why?
|
| Debridement | 12 | 2019 | 104 | 1.190 |
Why?
|
| Bone Resorption | 7 | 2019 | 83 | 1.170 |
Why?
|
| Risk Factors | 21 | 2021 | 2173 | 1.160 |
Why?
|
| Ambulatory Surgical Procedures | 5 | 2020 | 72 | 1.140 |
Why?
|
| Age Factors | 12 | 2020 | 738 | 1.130 |
Why?
|
| Imaging, Three-Dimensional | 13 | 2021 | 196 | 1.110 |
Why?
|
| Cartilage, Articular | 12 | 2018 | 418 | 1.070 |
Why?
|
| Humeral Fractures | 3 | 2017 | 22 | 1.070 |
Why?
|
| Treatment Failure | 9 | 2020 | 149 | 1.070 |
Why?
|
| Evidence-Based Medicine | 8 | 2020 | 162 | 1.070 |
Why?
|
| Surveys and Questionnaires | 18 | 2019 | 1083 | 1.040 |
Why?
|
| Cohort Studies | 19 | 2020 | 1815 | 1.020 |
Why?
|
| Cumulative Trauma Disorders | 4 | 2016 | 17 | 1.010 |
Why?
|
| Recurrence | 20 | 2021 | 290 | 0.990 |
Why?
|
| Return to Work | 5 | 2021 | 62 | 0.980 |
Why?
|
| Patient Reported Outcome Measures | 14 | 2021 | 501 | 0.960 |
Why?
|
| Lacerations | 3 | 2015 | 16 | 0.950 |
Why?
|
| Rupture | 14 | 2019 | 111 | 0.950 |
Why?
|
| Internship and Residency | 4 | 2019 | 206 | 0.930 |
Why?
|
| Surgeons | 3 | 2020 | 86 | 0.900 |
Why?
|
| Joint Diseases | 11 | 2019 | 116 | 0.880 |
Why?
|
| Arthritis | 5 | 2020 | 52 | 0.880 |
Why?
|
| Platelet-Rich Plasma | 7 | 2017 | 85 | 0.880 |
Why?
|
| Magnetic Resonance Imaging | 16 | 2023 | 1071 | 0.870 |
Why?
|
| Surgical Wound Infection | 4 | 2020 | 85 | 0.870 |
Why?
|
| Wound Healing | 12 | 2021 | 153 | 0.850 |
Why?
|
| Iatrogenic Disease | 2 | 2020 | 24 | 0.810 |
Why?
|
| Length of Stay | 6 | 2021 | 307 | 0.810 |
Why?
|
| Peripheral Nerve Injuries | 4 | 2020 | 16 | 0.800 |
Why?
|
| Prosthesis Design | 12 | 2020 | 477 | 0.790 |
Why?
|
| Weight-Bearing | 6 | 2020 | 157 | 0.770 |
Why?
|
| Child | 16 | 2021 | 1180 | 0.760 |
Why?
|
| Nerve Compression Syndromes | 4 | 2010 | 17 | 0.760 |
Why?
|
| Propionibacterium acnes | 2 | 2020 | 7 | 0.750 |
Why?
|
| Postoperative Care | 12 | 2020 | 134 | 0.750 |
Why?
|
| Occupational Injuries | 2 | 2019 | 8 | 0.750 |
Why?
|
| Fractures, Stress | 2 | 2019 | 20 | 0.740 |
Why?
|
| Nanofibers | 1 | 2021 | 1 | 0.740 |
Why?
|
| Humeral Head | 7 | 2021 | 37 | 0.730 |
Why?
|
| Incidence | 10 | 2019 | 720 | 0.730 |
Why?
|
| Muscular Dystrophy, Facioscapulohumeral | 2 | 2012 | 2 | 0.720 |
Why?
|
| Ribs | 2 | 2012 | 14 | 0.710 |
Why?
|
| Physical Examination | 9 | 2018 | 115 | 0.690 |
Why?
|
| Absorbable Implants | 6 | 2021 | 27 | 0.680 |
Why?
|
| Venous Thromboembolism | 1 | 2021 | 36 | 0.680 |
Why?
|
| Education, Medical, Graduate | 3 | 2019 | 77 | 0.660 |
Why?
|
| Physical Therapy Modalities | 4 | 2018 | 73 | 0.660 |
Why?
|
| Elbow | 4 | 2021 | 49 | 0.660 |
Why?
|
| Patient Outcome Assessment | 2 | 2017 | 32 | 0.640 |
Why?
|
| Clavicle | 4 | 2016 | 13 | 0.630 |
Why?
|
| Sternoclavicular Joint | 1 | 2019 | 6 | 0.630 |
Why?
|
| Olecranon Process | 1 | 2019 | 3 | 0.630 |
Why?
|
| Ulnar Nerve | 1 | 2019 | 2 | 0.620 |
Why?
|
| Electromyography | 4 | 2017 | 71 | 0.620 |
Why?
|
| Ulnar Nerve Compression Syndromes | 1 | 2019 | 2 | 0.620 |
Why?
|
| Opioid-Related Disorders | 2 | 2019 | 61 | 0.620 |
Why?
|
| Patient Selection | 5 | 2013 | 182 | 0.610 |
Why?
|
| Elective Surgical Procedures | 1 | 2019 | 36 | 0.610 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 78 | 0.600 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 82 | 0.600 |
Why?
|
| Arm Injuries | 2 | 2016 | 8 | 0.590 |
Why?
|
| Sex Factors | 4 | 2017 | 453 | 0.590 |
Why?
|
| Pandemics | 1 | 2020 | 221 | 0.590 |
Why?
|
| Arm | 8 | 2022 | 83 | 0.590 |
Why?
|
| Health Care Surveys | 2 | 2017 | 62 | 0.580 |
Why?
|
| Doxycycline | 1 | 2018 | 15 | 0.580 |
Why?
|
| Joint Capsule Release | 1 | 2018 | 12 | 0.570 |
Why?
|
| Exercise Therapy | 3 | 2017 | 82 | 0.570 |
Why?
|
| Coracoid Process | 2 | 2017 | 7 | 0.570 |
Why?
|
| Bursitis | 1 | 2018 | 13 | 0.560 |
Why?
|
| Pelvic Exenteration | 1 | 2017 | 1 | 0.560 |
Why?
|
| Disease Management | 1 | 2018 | 91 | 0.560 |
Why?
|
| Prospective Studies | 13 | 2023 | 1686 | 0.560 |
Why?
|
| Pneumonia | 1 | 2018 | 67 | 0.550 |
Why?
|
| Body Mass Index | 3 | 2020 | 431 | 0.550 |
Why?
|
| Pulmonary Embolism | 1 | 2018 | 54 | 0.550 |
Why?
|
| Fever | 1 | 2017 | 33 | 0.550 |
Why?
|
| Hospital Charges | 1 | 2017 | 17 | 0.550 |
Why?
|
| Genital Neoplasms, Female | 1 | 2017 | 14 | 0.550 |
Why?
|
| Pain, Postoperative | 3 | 2019 | 313 | 0.550 |
Why?
|
| Analgesics, Opioid | 2 | 2020 | 228 | 0.540 |
Why?
|
| Muscle Fatigue | 2 | 2017 | 11 | 0.540 |
Why?
|
| Patient Positioning | 5 | 2020 | 36 | 0.530 |
Why?
|
| Ilium | 2 | 2014 | 29 | 0.530 |
Why?
|
| Dyskinesias | 1 | 2016 | 10 | 0.520 |
Why?
|
| Acellular Dermis | 2 | 2013 | 7 | 0.520 |
Why?
|
| Transplantation, Homologous | 10 | 2018 | 260 | 0.520 |
Why?
|
| Osteochondritis Dissecans | 3 | 2015 | 26 | 0.520 |
Why?
|
| Allografts | 7 | 2021 | 211 | 0.520 |
Why?
|
| Prosthesis-Related Infections | 2 | 2019 | 187 | 0.520 |
Why?
|
| Finite Element Analysis | 1 | 2016 | 29 | 0.510 |
Why?
|
| Case-Control Studies | 8 | 2017 | 567 | 0.510 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 193 | 0.500 |
Why?
|
| Transplantation, Autologous | 8 | 2019 | 150 | 0.490 |
Why?
|
| Minimal Clinically Important Difference | 4 | 2021 | 166 | 0.480 |
Why?
|
| Quality Improvement | 1 | 2016 | 130 | 0.480 |
Why?
|
| Menisci, Tibial | 3 | 2013 | 173 | 0.480 |
Why?
|
| Tennis Elbow | 3 | 2010 | 16 | 0.470 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 375 | 0.470 |
Why?
|
| Workers' Compensation | 6 | 2021 | 70 | 0.460 |
Why?
|
| Shoulder Impingement Syndrome | 2 | 2014 | 14 | 0.450 |
Why?
|
| Computer Simulation | 5 | 2019 | 176 | 0.440 |
Why?
|
| Wounds and Injuries | 3 | 2011 | 44 | 0.430 |
Why?
|
| Risk Assessment | 9 | 2021 | 553 | 0.430 |
Why?
|
| Skin Transplantation | 1 | 2013 | 11 | 0.410 |
Why?
|
| Radius | 3 | 2018 | 33 | 0.410 |
Why?
|
| Reproducibility of Results | 7 | 2020 | 619 | 0.410 |
Why?
|
| Salvage Therapy | 3 | 2020 | 34 | 0.410 |
Why?
|
| Foreign-Body Reaction | 1 | 2013 | 26 | 0.400 |
Why?
|
| Joint Capsule | 4 | 2008 | 60 | 0.400 |
Why?
|
| Pain | 6 | 2022 | 401 | 0.400 |
Why?
|
| Preoperative Period | 4 | 2020 | 79 | 0.390 |
Why?
|
| Cartilage | 1 | 2013 | 103 | 0.390 |
Why?
|
| Movement | 4 | 2016 | 110 | 0.390 |
Why?
|
| Brachial Plexus Neuropathies | 1 | 2012 | 5 | 0.380 |
Why?
|
| Hand Injuries | 2 | 2009 | 10 | 0.380 |
Why?
|
| Monitoring, Intraoperative | 1 | 2012 | 32 | 0.380 |
Why?
|
| Arthrodesis | 1 | 2012 | 39 | 0.370 |
Why?
|
| Preoperative Care | 7 | 2020 | 119 | 0.370 |
Why?
|
| Arthroplasty, Subchondral | 3 | 2019 | 30 | 0.350 |
Why?
|
| Arthralgia | 4 | 2016 | 134 | 0.340 |
Why?
|
| Diagnosis, Differential | 5 | 2013 | 328 | 0.340 |
Why?
|
| Comorbidity | 5 | 2020 | 457 | 0.330 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2020 | 51 | 0.320 |
Why?
|
| Algorithms | 4 | 2019 | 337 | 0.320 |
Why?
|
| Competitive Behavior | 2 | 2019 | 3 | 0.310 |
Why?
|
| Visual Analog Scale | 3 | 2019 | 84 | 0.310 |
Why?
|
| Inpatients | 2 | 2021 | 121 | 0.290 |
Why?
|
| Cross-Sectional Studies | 3 | 2016 | 847 | 0.290 |
Why?
|
| Chondrocytes | 3 | 2012 | 155 | 0.290 |
Why?
|
| Simulation Training | 2 | 2019 | 38 | 0.280 |
Why?
|
| Societies, Medical | 3 | 2018 | 118 | 0.280 |
Why?
|
| Disability Evaluation | 3 | 2019 | 257 | 0.280 |
Why?
|
| Sheep | 3 | 2023 | 18 | 0.280 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2010 | 307 | 0.280 |
Why?
|
| Clinical Competence | 3 | 2019 | 201 | 0.280 |
Why?
|
| Neurosurgical Procedures | 1 | 2009 | 145 | 0.270 |
Why?
|
| Sutures | 5 | 2019 | 51 | 0.270 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2017 | 103 | 0.270 |
Why?
|
| Deltoid Muscle | 2 | 2018 | 6 | 0.270 |
Why?
|
| Transplants | 2 | 2016 | 10 | 0.260 |
Why?
|
| Arthrography | 4 | 2017 | 29 | 0.250 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2015 | 161 | 0.250 |
Why?
|
| Equipment Design | 6 | 2020 | 126 | 0.250 |
Why?
|
| Diagnostic Imaging | 4 | 2016 | 77 | 0.250 |
Why?
|
| Software | 3 | 2022 | 60 | 0.250 |
Why?
|
| Stress, Mechanical | 6 | 2019 | 155 | 0.250 |
Why?
|
| Body Height | 2 | 2015 | 35 | 0.230 |
Why?
|
| Polyethylene | 3 | 2020 | 124 | 0.230 |
Why?
|
| Tendon Transfer | 2 | 2015 | 18 | 0.230 |
Why?
|
| Severity of Illness Index | 5 | 2016 | 830 | 0.230 |
Why?
|
| Hospitalization | 4 | 2020 | 295 | 0.230 |
Why?
|
| Meta-Analysis as Topic | 2 | 2014 | 40 | 0.220 |
Why?
|
| Fractures, Bone | 2 | 2016 | 73 | 0.220 |
Why?
|
| Odds Ratio | 3 | 2019 | 254 | 0.220 |
Why?
|
| Knee Joint | 5 | 2015 | 758 | 0.220 |
Why?
|
| Prognosis | 6 | 2013 | 695 | 0.210 |
Why?
|
| Epilepsy | 3 | 2018 | 69 | 0.210 |
Why?
|
| Musculoskeletal Pain | 3 | 2020 | 20 | 0.210 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2018 | 106 | 0.210 |
Why?
|
| Animals | 7 | 2023 | 3504 | 0.210 |
Why?
|
| Muscle Strength | 4 | 2017 | 129 | 0.210 |
Why?
|
| Osteonecrosis | 2 | 2005 | 16 | 0.210 |
Why?
|
| Extracellular Vesicles | 1 | 2023 | 2 | 0.210 |
Why?
|
| Patient Safety | 2 | 2020 | 33 | 0.210 |
Why?
|
| Exosomes | 1 | 2023 | 6 | 0.200 |
Why?
|
| Prosthesis Failure | 3 | 2019 | 518 | 0.200 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2014 | 264 | 0.200 |
Why?
|
| Axilla | 2 | 2021 | 14 | 0.200 |
Why?
|
| Activities of Daily Living | 5 | 2020 | 584 | 0.200 |
Why?
|
| Machine Learning | 2 | 2022 | 79 | 0.200 |
Why?
|
| Blood Transfusion | 3 | 2019 | 62 | 0.200 |
Why?
|
| Tensile Strength | 3 | 2019 | 23 | 0.200 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 589 | 0.200 |
Why?
|
| Posture | 2 | 2015 | 60 | 0.190 |
Why?
|
| Workload | 2 | 2021 | 25 | 0.190 |
Why?
|
| Operative Time | 3 | 2019 | 84 | 0.190 |
Why?
|
| Biological Products | 1 | 2023 | 41 | 0.190 |
Why?
|
| Equipment Failure | 4 | 2017 | 37 | 0.190 |
Why?
|
| Torque | 4 | 2017 | 23 | 0.190 |
Why?
|
| Depressive Disorder | 1 | 2023 | 168 | 0.190 |
Why?
|
| Patient Discharge | 2 | 2020 | 147 | 0.190 |
Why?
|
| Health Care Costs | 2 | 2022 | 69 | 0.190 |
Why?
|
| Random Allocation | 6 | 2019 | 123 | 0.190 |
Why?
|
| Fibrocartilage | 2 | 2015 | 9 | 0.190 |
Why?
|
| Injections, Intra-Articular | 2 | 2019 | 92 | 0.180 |
Why?
|
| Thoracic Outlet Syndrome | 1 | 2001 | 1 | 0.180 |
Why?
|
| Bone Density | 4 | 2013 | 143 | 0.180 |
Why?
|
| Artificial Limbs | 1 | 2021 | 5 | 0.180 |
Why?
|
| Bone Wires | 2 | 2012 | 10 | 0.180 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2019 | 63 | 0.180 |
Why?
|
| Skin | 2 | 2020 | 126 | 0.180 |
Why?
|
| Medicare | 2 | 2021 | 116 | 0.170 |
Why?
|
| Patient-Specific Modeling | 1 | 2020 | 2 | 0.170 |
Why?
|
| Health Care Sector | 1 | 2020 | 5 | 0.170 |
Why?
|
| Bone Cements | 2 | 2020 | 85 | 0.170 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 10 | 0.170 |
Why?
|
| Materials Testing | 3 | 2017 | 122 | 0.170 |
Why?
|
| Calibration | 1 | 2020 | 19 | 0.170 |
Why?
|
| Ulnar Neuropathies | 1 | 2020 | 4 | 0.170 |
Why?
|
| Sheep Diseases | 1 | 2020 | 1 | 0.170 |
Why?
|
| Chronic Disease | 4 | 2012 | 403 | 0.170 |
Why?
|
| Sex | 1 | 2020 | 1 | 0.170 |
Why?
|
| Frailty | 1 | 2020 | 30 | 0.170 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 41 | 0.170 |
Why?
|
| Perioperative Care | 1 | 2020 | 42 | 0.170 |
Why?
|
| Osseointegration | 1 | 2020 | 67 | 0.160 |
Why?
|
| Sprains and Strains | 1 | 2019 | 3 | 0.160 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2020 | 29 | 0.160 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2020 | 55 | 0.160 |
Why?
|
| Gender Identity | 1 | 2020 | 25 | 0.160 |
Why?
|
| Mental Recall | 1 | 2020 | 60 | 0.160 |
Why?
|
| Anesthesia, Conduction | 1 | 2020 | 32 | 0.160 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1999 | 26 | 0.160 |
Why?
|
| Football | 2 | 2017 | 38 | 0.160 |
Why?
|
| Weight Lifting | 1 | 2019 | 9 | 0.160 |
Why?
|
| Supervised Machine Learning | 1 | 2019 | 15 | 0.160 |
Why?
|
| Matched-Pair Analysis | 1 | 2019 | 29 | 0.160 |
Why?
|
| Betacoronavirus | 1 | 2020 | 67 | 0.160 |
Why?
|
| Infant | 5 | 2018 | 503 | 0.160 |
Why?
|
| Sports | 1 | 2020 | 60 | 0.160 |
Why?
|
| Autografts | 1 | 2019 | 29 | 0.150 |
Why?
|
| Electroencephalography | 3 | 2018 | 83 | 0.150 |
Why?
|
| Child, Preschool | 5 | 2018 | 590 | 0.150 |
Why?
|
| Ulna | 1 | 2019 | 31 | 0.150 |
Why?
|
| Political Activism | 1 | 2018 | 1 | 0.150 |
Why?
|
| Sex Characteristics | 1 | 2020 | 115 | 0.150 |
Why?
|
| Depression | 2 | 2020 | 410 | 0.150 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 143 | 0.150 |
Why?
|
| Physical Exertion | 1 | 2018 | 3 | 0.150 |
Why?
|
| Osteolysis | 2 | 2017 | 139 | 0.150 |
Why?
|
| Orthopedic Nursing | 1 | 1998 | 2 | 0.150 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 309 | 0.150 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2018 | 12 | 0.150 |
Why?
|
| Health Policy | 1 | 2018 | 41 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2013 | 201 | 0.150 |
Why?
|
| Tissue Transplantation | 2 | 2016 | 18 | 0.150 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 96 | 0.150 |
Why?
|
| Patient Compliance | 2 | 2017 | 145 | 0.140 |
Why?
|
| Chromosome Disorders | 1 | 2018 | 14 | 0.140 |
Why?
|
| Pleura | 1 | 2017 | 9 | 0.140 |
Why?
|
| Pleural Neoplasms | 1 | 2017 | 10 | 0.140 |
Why?
|
| Models, Biological | 4 | 2013 | 285 | 0.140 |
Why?
|
| Mesothelioma | 1 | 2017 | 13 | 0.140 |
Why?
|
| Female Athlete Triad Syndrome | 1 | 2017 | 3 | 0.140 |
Why?
|
| Urinary Diversion | 1 | 2017 | 1 | 0.140 |
Why?
|
| Leg Injuries | 1 | 2017 | 7 | 0.140 |
Why?
|
| Fracture Fixation | 3 | 2015 | 21 | 0.140 |
Why?
|
| Brain Concussion | 1 | 2017 | 15 | 0.140 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2017 | 33 | 0.140 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 149 | 0.140 |
Why?
|
| Osteoporosis | 1 | 2018 | 74 | 0.140 |
Why?
|
| Insurance Claim Review | 1 | 2017 | 8 | 0.130 |
Why?
|
| Decision Support Techniques | 2 | 2016 | 45 | 0.130 |
Why?
|
| Tarsal Bones | 1 | 2016 | 4 | 0.130 |
Why?
|
| Patient Preference | 1 | 2017 | 33 | 0.130 |
Why?
|
| Outpatients | 1 | 2017 | 54 | 0.130 |
Why?
|
| Cell Proliferation | 2 | 2015 | 177 | 0.130 |
Why?
|
| Electronic Health Records | 1 | 2017 | 71 | 0.130 |
Why?
|
| Pressure | 2 | 2014 | 62 | 0.130 |
Why?
|
| Lower Extremity | 1 | 2017 | 36 | 0.130 |
Why?
|
| Hyaline Cartilage | 2 | 2013 | 14 | 0.130 |
Why?
|
| Trauma Severity Indices | 1 | 1996 | 9 | 0.130 |
Why?
|
| Track and Field | 1 | 2016 | 1 | 0.130 |
Why?
|
| Prostheses and Implants | 1 | 2017 | 152 | 0.120 |
Why?
|
| Surgical Tape | 1 | 2015 | 3 | 0.120 |
Why?
|
| Orthopedic Surgeons | 1 | 2016 | 27 | 0.120 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2015 | 46 | 0.120 |
Why?
|
| Anterior Cruciate Ligament Injuries | 1 | 2017 | 195 | 0.120 |
Why?
|
| Cartilage Diseases | 1 | 2017 | 94 | 0.120 |
Why?
|
| Sensitivity and Specificity | 4 | 2013 | 450 | 0.120 |
Why?
|
| Chondrogenesis | 1 | 2015 | 32 | 0.120 |
Why?
|
| Clinical Trials as Topic | 2 | 2013 | 196 | 0.120 |
Why?
|
| Propensity Score | 1 | 2015 | 31 | 0.120 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2018 | 251 | 0.120 |
Why?
|
| Thoracic Nerves | 1 | 2015 | 3 | 0.120 |
Why?
|
| Mononeuropathies | 1 | 2015 | 3 | 0.120 |
Why?
|
| Video Recording | 1 | 2015 | 31 | 0.120 |
Why?
|
| Paralysis | 1 | 2015 | 15 | 0.120 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2012 | 53 | 0.110 |
Why?
|
| Thoracic Wall | 2 | 2012 | 12 | 0.110 |
Why?
|
| Functional Laterality | 2 | 2015 | 62 | 0.110 |
Why?
|
| Ultrasonography | 3 | 2017 | 221 | 0.110 |
Why?
|
| Reference Values | 3 | 2010 | 175 | 0.110 |
Why?
|
| Cytokines | 1 | 2015 | 231 | 0.110 |
Why?
|
| Boronic Acids | 1 | 2013 | 4 | 0.110 |
Why?
|
| Pyrazines | 1 | 2013 | 9 | 0.110 |
Why?
|
| Radiology | 1 | 2013 | 16 | 0.110 |
Why?
|
| Multiple Myeloma | 1 | 2013 | 18 | 0.110 |
Why?
|
| Models, Educational | 1 | 2013 | 25 | 0.110 |
Why?
|
| Immunocompromised Host | 1 | 2013 | 42 | 0.110 |
Why?
|
| Computer-Assisted Instruction | 1 | 2013 | 20 | 0.110 |
Why?
|
| Internet | 1 | 2014 | 85 | 0.110 |
Why?
|
| Education, Medical, Continuing | 1 | 2013 | 31 | 0.100 |
Why?
|
| Injury Severity Score | 1 | 2013 | 13 | 0.100 |
Why?
|
| Stem Cell Transplantation | 1 | 2013 | 42 | 0.100 |
Why?
|
| Cytomegalovirus Infections | 1 | 2013 | 34 | 0.100 |
Why?
|
| Glycoproteins | 2 | 2005 | 49 | 0.100 |
Why?
|
| Linear Models | 1 | 2013 | 241 | 0.100 |
Why?
|
| Feasibility Studies | 1 | 2013 | 200 | 0.100 |
Why?
|
| Joint Dislocations | 1 | 2013 | 56 | 0.100 |
Why?
|
| Guideline Adherence | 1 | 2013 | 52 | 0.100 |
Why?
|
| Acute Disease | 1 | 2013 | 165 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 540 | 0.100 |
Why?
|
| Models, Anatomic | 2 | 2013 | 37 | 0.100 |
Why?
|
| Osteocytes | 1 | 2012 | 18 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 160 | 0.100 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 2012 | 8 | 0.100 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2012 | 42 | 0.100 |
Why?
|
| Secondary Prevention | 1 | 2012 | 50 | 0.100 |
Why?
|
| Osteochondritis | 1 | 2011 | 3 | 0.090 |
Why?
|
| Femur | 1 | 2015 | 374 | 0.090 |
Why?
|
| Research Design | 1 | 2013 | 176 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 251 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 3 | 2016 | 123 | 0.090 |
Why?
|
| Device Removal | 1 | 2011 | 80 | 0.090 |
Why?
|
| Bone Marrow | 2 | 2023 | 71 | 0.090 |
Why?
|
| Dermis | 2 | 2020 | 8 | 0.090 |
Why?
|
| Work Capacity Evaluation | 1 | 2010 | 8 | 0.080 |
Why?
|
| Confidence Intervals | 1 | 2009 | 88 | 0.080 |
Why?
|
| Adenoma, Pleomorphic | 1 | 2008 | 6 | 0.080 |
Why?
|
| Intraoperative Complications | 1 | 2009 | 65 | 0.080 |
Why?
|
| Radiographic Image Enhancement | 1 | 2008 | 25 | 0.070 |
Why?
|
| Musculoskeletal Diseases | 1 | 2009 | 41 | 0.070 |
Why?
|
| Parotid Neoplasms | 1 | 2008 | 14 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2019 | 394 | 0.070 |
Why?
|
| Forecasting | 2 | 2019 | 91 | 0.070 |
Why?
|
| Current Procedural Terminology | 2 | 2019 | 11 | 0.070 |
Why?
|
| Regression Analysis | 3 | 2014 | 246 | 0.070 |
Why?
|
| Therapeutic Community | 1 | 2007 | 1 | 0.070 |
Why?
|
| Character | 1 | 2007 | 3 | 0.070 |
Why?
|
| Temperament | 1 | 2007 | 11 | 0.070 |
Why?
|
| Patient Dropouts | 1 | 2007 | 24 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2008 | 169 | 0.070 |
Why?
|
| Braces | 1 | 2006 | 23 | 0.060 |
Why?
|
| Ultrasonic Therapy | 1 | 2006 | 22 | 0.060 |
Why?
|
| Electrocoagulation | 1 | 2005 | 12 | 0.060 |
Why?
|
| Hemostasis, Surgical | 1 | 2005 | 13 | 0.060 |
Why?
|
| Bursa, Synovial | 1 | 2005 | 10 | 0.060 |
Why?
|
| Internal Fixators | 1 | 2005 | 37 | 0.060 |
Why?
|
| Hemodiafiltration | 1 | 2005 | 2 | 0.060 |
Why?
|
| Chronic Kidney Disease-Mineral and Bone Disorder | 1 | 2005 | 3 | 0.060 |
Why?
|
| Burns | 1 | 2005 | 18 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2005 | 27 | 0.060 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2005 | 24 | 0.060 |
Why?
|
| Collagen Type III | 2 | 2015 | 12 | 0.060 |
Why?
|
| Collagen Type I | 2 | 2015 | 20 | 0.060 |
Why?
|
| Bone and Bones | 1 | 2005 | 116 | 0.050 |
Why?
|
| Surgical Instruments | 1 | 2004 | 20 | 0.050 |
Why?
|
| Anterior Cruciate Ligament | 1 | 2005 | 182 | 0.050 |
Why?
|
| Kidney Failure, Chronic | 1 | 2005 | 110 | 0.050 |
Why?
|
| Medical Illustration | 2 | 2015 | 13 | 0.050 |
Why?
|
| Tenocytes | 1 | 2023 | 1 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 149 | 0.050 |
Why?
|
| Disease Progression | 2 | 2018 | 646 | 0.050 |
Why?
|
| Decision Making | 1 | 2005 | 214 | 0.050 |
Why?
|
| Intraoperative Period | 1 | 2002 | 22 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 2004 | 143 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2015 | 506 | 0.050 |
Why?
|
| Macrophages | 1 | 2023 | 108 | 0.050 |
Why?
|
| Status Epilepticus | 2 | 1995 | 12 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2023 | 76 | 0.050 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 2002 | 1 | 0.050 |
Why?
|
| Prothrombin | 1 | 2002 | 4 | 0.050 |
Why?
|
| Rest | 1 | 2021 | 32 | 0.050 |
Why?
|
| Nomograms | 1 | 2021 | 6 | 0.050 |
Why?
|
| Arthroscopes | 1 | 2001 | 7 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 286 | 0.050 |
Why?
|
| Rabbits | 2 | 2015 | 178 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2021 | 27 | 0.040 |
Why?
|
| Cubital Tunnel Syndrome | 1 | 2020 | 4 | 0.040 |
Why?
|
| Consensus | 1 | 2021 | 91 | 0.040 |
Why?
|
| Bone-Implant Interface | 1 | 2019 | 7 | 0.040 |
Why?
|
| Hematocrit | 1 | 2019 | 13 | 0.040 |
Why?
|
| Episode of Care | 1 | 2019 | 6 | 0.040 |
Why?
|
| Color | 1 | 1999 | 6 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2019 | 25 | 0.040 |
Why?
|
| Eyeglasses | 1 | 1999 | 3 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2019 | 61 | 0.040 |
Why?
|
| Skilled Nursing Facilities | 1 | 2019 | 31 | 0.040 |
Why?
|
| Running | 1 | 1999 | 12 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 131 | 0.040 |
Why?
|
| Basketball | 1 | 1999 | 11 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2019 | 19 | 0.040 |
Why?
|
| Light | 1 | 1999 | 56 | 0.040 |
Why?
|
| Receptors, Somatostatin | 1 | 1998 | 1 | 0.040 |
Why?
|
| Patella | 1 | 1999 | 72 | 0.040 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1998 | 13 | 0.040 |
Why?
|
| Risk | 1 | 2019 | 202 | 0.040 |
Why?
|
| Smoking | 1 | 2019 | 173 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 421 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2018 | 4 | 0.040 |
Why?
|
| Operating Rooms | 1 | 2018 | 14 | 0.040 |
Why?
|
| Benzophenones | 1 | 2017 | 25 | 0.040 |
Why?
|
| Ketones | 1 | 2017 | 20 | 0.040 |
Why?
|
| Polymers | 1 | 2017 | 42 | 0.040 |
Why?
|
| Neuroendocrine Tumors | 1 | 1998 | 51 | 0.040 |
Why?
|
| Michigan | 1 | 2017 | 17 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2017 | 38 | 0.030 |
Why?
|
| Reimbursement, Incentive | 1 | 2017 | 7 | 0.030 |
Why?
|
| Health Status Indicators | 2 | 2010 | 67 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2010 | 248 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 1 | 1998 | 90 | 0.030 |
Why?
|
| Seizures | 1 | 2018 | 70 | 0.030 |
Why?
|
| Quality of Life | 1 | 2021 | 563 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 189 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2017 | 23 | 0.030 |
Why?
|
| Torso | 1 | 2017 | 7 | 0.030 |
Why?
|
| Knee | 1 | 2017 | 45 | 0.030 |
Why?
|
| Knee Injuries | 1 | 1999 | 202 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 1996 | 29 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2016 | 21 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 83 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2015 | 3 | 0.030 |
Why?
|
| Angelman Syndrome | 1 | 1995 | 2 | 0.030 |
Why?
|
| Epilepsies, Partial | 1 | 1995 | 14 | 0.030 |
Why?
|
| Probability | 2 | 2006 | 84 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2015 | 20 | 0.030 |
Why?
|
| Photography | 1 | 2015 | 15 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 40 | 0.030 |
Why?
|
| Biocompatible Materials | 1 | 2016 | 88 | 0.030 |
Why?
|
| Sports Medicine | 1 | 2016 | 36 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 89 | 0.030 |
Why?
|
| Tissue Scaffolds | 1 | 2015 | 26 | 0.030 |
Why?
|
| Models, Animal | 1 | 2015 | 108 | 0.030 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 30 | 0.030 |
Why?
|
| X-Ray Microtomography | 1 | 2015 | 80 | 0.030 |
Why?
|
| Thorax | 1 | 2014 | 11 | 0.030 |
Why?
|
| Endoscopy | 1 | 1996 | 176 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 190 | 0.030 |
Why?
|
| Bortezomib | 1 | 2013 | 3 | 0.030 |
Why?
|
| Vincristine | 1 | 2013 | 20 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2013 | 13 | 0.030 |
Why?
|
| Decision Trees | 1 | 2013 | 14 | 0.030 |
Why?
|
| Markov Chains | 1 | 2013 | 31 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2013 | 32 | 0.030 |
Why?
|
| Learning Curve | 1 | 2013 | 18 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2013 | 33 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2013 | 47 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2013 | 33 | 0.030 |
Why?
|
| Decorin | 1 | 2013 | 5 | 0.030 |
Why?
|
| Tenascin | 1 | 2013 | 4 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2013 | 96 | 0.030 |
Why?
|
| Hip | 1 | 2013 | 67 | 0.030 |
Why?
|
| Blood Specimen Collection | 1 | 2012 | 5 | 0.020 |
Why?
|
| Observer Variation | 1 | 2012 | 95 | 0.020 |
Why?
|
| Erythrocytes | 1 | 2012 | 18 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2012 | 35 | 0.020 |
Why?
|
| Leukocytes | 1 | 2012 | 34 | 0.020 |
Why?
|
| Ankle Joint | 1 | 2011 | 42 | 0.020 |
Why?
|
| Transducers | 1 | 2010 | 10 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2010 | 153 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 116 | 0.020 |
Why?
|
| Occupations | 1 | 2010 | 18 | 0.020 |
Why?
|
| Medical History Taking | 1 | 2010 | 30 | 0.020 |
Why?
|
| Anticonvulsants | 2 | 2002 | 54 | 0.020 |
Why?
|
| Gymnastics | 1 | 2010 | 4 | 0.020 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2008 | 5 | 0.020 |
Why?
|
| Adenolymphoma | 1 | 2008 | 4 | 0.020 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2008 | 4 | 0.020 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2008 | 11 | 0.020 |
Why?
|
| Substance P | 1 | 2008 | 10 | 0.020 |
Why?
|
| Contrast Media | 1 | 2008 | 58 | 0.020 |
Why?
|
| Axons | 1 | 2008 | 28 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2008 | 96 | 0.020 |
Why?
|
| Seizures, Febrile | 1 | 1987 | 2 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 355 | 0.020 |
Why?
|
| Italy | 1 | 2007 | 13 | 0.020 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2007 | 38 | 0.020 |
Why?
|
| Personality Assessment | 1 | 2007 | 33 | 0.020 |
Why?
|
| Compressive Strength | 1 | 2006 | 17 | 0.020 |
Why?
|
| Personality Inventory | 1 | 2007 | 73 | 0.020 |
Why?
|
| Social Adjustment | 1 | 2007 | 23 | 0.020 |
Why?
|
| Inflammation | 1 | 2008 | 277 | 0.020 |
Why?
|
| Brain | 1 | 1995 | 1604 | 0.020 |
Why?
|
| Motivation | 1 | 2007 | 89 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2007 | 291 | 0.020 |
Why?
|
| Selection Bias | 1 | 2005 | 9 | 0.010 |
Why?
|
| Equipment Safety | 1 | 2005 | 7 | 0.010 |
Why?
|
| Fractures, Spontaneous | 1 | 2005 | 8 | 0.010 |
Why?
|
| Hip Joint | 1 | 2011 | 555 | 0.010 |
Why?
|
| Bone Marrow Diseases | 1 | 2005 | 7 | 0.010 |
Why?
|
| Connective Tissue | 1 | 2005 | 24 | 0.010 |
Why?
|
| Osteoprotegerin | 1 | 2005 | 5 | 0.010 |
Why?
|
| Edema | 1 | 2005 | 25 | 0.010 |
Why?
|
| Image Enhancement | 1 | 2005 | 45 | 0.010 |
Why?
|
| Absorptiometry, Photon | 1 | 2005 | 79 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2004 | 12 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2004 | 49 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2004 | 37 | 0.010 |
Why?
|
| Cisplatin | 1 | 2004 | 55 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2004 | 339 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2007 | 1324 | 0.010 |
Why?
|
| beta 2-Glycoprotein I | 1 | 2002 | 7 | 0.010 |
Why?
|
| Seroepidemiologic Studies | 1 | 2002 | 18 | 0.010 |
Why?
|
| Biomarkers | 1 | 2005 | 536 | 0.010 |
Why?
|
| Prosthesis Implantation | 1 | 2001 | 26 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2002 | 553 | 0.010 |
Why?
|
| Videotape Recording | 1 | 1999 | 18 | 0.010 |
Why?
|
| Photic Stimulation | 1 | 1999 | 25 | 0.010 |
Why?
|
| Elasticity | 1 | 1999 | 28 | 0.010 |
Why?
|
| Reaction Time | 1 | 1999 | 99 | 0.010 |
Why?
|
| Action Potentials | 1 | 1999 | 82 | 0.010 |
Why?
|
| Whole-Body Counting | 1 | 1998 | 2 | 0.010 |
Why?
|
| Somatostatin | 1 | 1998 | 2 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1998 | 34 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 1998 | 46 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 1998 | 102 | 0.010 |
Why?
|
| Movement Disorders | 1 | 1995 | 67 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 1987 | 118 | 0.000 |
Why?
|